The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.
Vigilant Biosciences Aims to Lower Oral Cancer Mortality with Simple Screening Test
Nearly 40 percent of oral cancer patients will die within five years of diagnosis.
Mirna Therapeutics Uses Synthetic miRNA to Fight Disease
Researchers discovered that miRNA plays an important role in a process known as transcription. .Since its miRNA is a mimic, it has the same sequence as the natural miRNA found in cells.
Excelimmune Optimizes the Natural Power of the Immune System
MRSA, which is commonly acquired through contact within the community, is resistant to most first-line antimicrobials on the market.
This Week in Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
This Week in Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Kimberly Ha of BioPharm Insight Identifies Disruptive Trends and Technologies in Biotechnology
Kimberly Ha notes that many big pharma companies are partnering with academic institutions and that oncology, followed by neurology is one of the hottest areas in acquisitions
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
